Table 5.
Tumor markers for metastatic lung cancer sites.
| Author | Year | Histopathological Type | Metastatic sites | Risk factor |
|---|---|---|---|---|
| Pollán et al. (47) | 2003 | NSCLC | NS | p53, c-erbB-2, CEA, CA125 |
| Arrieta et al. (48) | 2009 | NSCLC | Brain | CEA |
| Cabrera-Alarcon et al. (49) | 2011 | NSCLC | NS | CYFRA 21-1 |
| Chen et al. (50) | 2015 | NS | Lymph node | CYFRA 21-1,CEA |
| Chen et al. (51) | 2015 | NSCLC | Brain | NSE |
| Zhou et al. (52) | 2017 | NS | Bone | CA-125, ALP |
| Morita et al. (53) | 2019 | SCLC | Intertrabecular Vertebral | CEA |
| Lin et al. (54) | 2020 | NS | Intraocular | CA153, CYFRA 21-1 |
NS, not specific; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; CEA, carcinoembryonic antigen; NSE, serum neuron-specific enolase; ALP, alkaline phosphate; CA, cancer antigen.